BLZF1

Across TCGA pan-cancer cohorts, BLZF1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated BLZF1 data layer compared with 27 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher BLZF1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated BLZF1 expression acts as an unfavorable survival marker, although some lineages such as HNSC and CCRCC show a favorable association.

HNSC, CCRCC, and LUAD are the cancer types where BLZF1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.827	0.478	<.001	88	view →
CCRCC	OS	Median	IV	0.785	0.123	.014	11	view →
LUAD	OS	Tertile	III,IV	0.879	0.525	.034	3	view →
PDAC	DFS	Quartile	All	0.234	0.485	.024	2	view →
LSCC	DFS	Quartile	II,III,IV	0.869	1.000	.024	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

BLZF1–HNSC (DFS)

Open the HNSC breakdown →